Stéphane Oudard

65.7k total citations · 13 hit papers
618 papers, 38.8k citations indexed

About

Stéphane Oudard is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Stéphane Oudard has authored 618 papers receiving a total of 38.8k indexed citations (citations by other indexed papers that have themselves been cited), including 471 papers in Pulmonary and Respiratory Medicine, 275 papers in Oncology and 181 papers in Cancer Research. Recurrent topics in Stéphane Oudard's work include Renal cell carcinoma treatment (228 papers), Prostate Cancer Treatment and Research (218 papers) and Renal and related cancers (103 papers). Stéphane Oudard is often cited by papers focused on Renal cell carcinoma treatment (228 papers), Prostate Cancer Treatment and Research (218 papers) and Renal and related cancers (103 papers). Stéphane Oudard collaborates with scholars based in France, United States and United Kingdom. Stéphane Oudard's co-authors include Thomas E. Hutson, Sylvie Négrier, Ronald M. Bukowski, Robert J. Motzer, Cezary Szczylik, Bernard Escudier, Robert A. Figlin, Piotr Tomczak, M. Dror Michaelson and Christine Théodore and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Stéphane Oudard

586 papers receiving 38.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2007 4.5k citations Robert J. Motzer, Thomas E. Hutson et al. profile →
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2004 4.3k citations Ronald de Wit, Stéphane Oudard et al. profile →
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Bernard Escudier, Tim Eisen et al. profile →
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

2010 2.4k citations Johann S. de Bono, Stéphane Oudard et al. The Lancet profile →
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
Phase 3 trial of everolimus for metastatic renal cell carcinoma

2010 903 citations Robert J. Motzer, Bernard Escudier et al. profile →
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

2018 868 citations Fred Saad, Stéphane Oudard et al. profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

2013 542 citations Robert J. Motzer, Bernard Escudier et al. profile →
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

2015 356 citations Nicolás A. Giraldo, Étienne Becht et al. Clinical Cancer Research profile →
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

2015 315 citations Frédéric Rolland, Stéphane Oudard et al. European Urology profile →
Bone health in cancer: ESMO Clinical Practice Guidelines

2020 294 citations Stéphane Oudard et al. profile →

Peers

Countries citing papers authored by Stéphane Oudard

Since Specialization

Citations

This map shows the geographic impact of Stéphane Oudard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Oudard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Oudard more than expected).

Fields of papers citing papers by Stéphane Oudard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Oudard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Oudard. The network helps show where Stéphane Oudard may publish in the future.

Co-authorship network of co-authors of Stéphane Oudard

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Oudard. A scholar is included among the top collaborators of Stéphane Oudard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Oudard. Stéphane Oudard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report 2024 ·European Annals of Otorhinolaryngology Head and Neck Diseases ·Claire Gervais, Édouard Auclin, (unknown), Gérémy Clair, Stéphane Oudard, H. Mirghani	0
2	CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Neeraj Agarwal, Arun Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard, Fred Saad, Axel S. Merseburger, Andrey Soares, Bradley A. McGregor, Bogdan Żurawski, Scott North, Marinos Tsiatas, Igor Bondarenko, (unknown), (unknown), Keerti Vardhan Sharma, (unknown), Roberta Ferraldeschi, Fong Wang, Sumanta K. Pal	20
3	Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma 2023 ·European Urology ·Thomas Powles, Zoe J. Assaf, Viraj Degaonkar, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Himanshu Sethi, Alexey Aleshin, Yi Shi, Nicole N. Davarpanah, Corey Carter, Joaquim Bellmunt, Sanjeev Mariathasan	61
4	OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC 2023 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), (unknown), Stéphane Oudard, (unknown), (unknown), (unknown), (unknown), Laura K. Aguilar, (unknown), Lorena Lupinacci, (unknown), Benjamin Besse, Laura Mezquita, Édouard Auclin	1
5	SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY 2023 ·Neuro-Oncology Advances ·Vivek Narayan, Othon Iliopoulos, (unknown), Benjamin L. Maughan, Kathryn E. Beckermann, Stéphane Oudard, Tobias Else, Jodi K. Maranchie, Wei Fu, Rodolfo F. Perini, Yanfang Liu, W. Marston Linehan, Ramaprasad Srinivasan, Eric Jonasch	1
6	Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel 2022 ·Cancers ·(unknown), Réza Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoît You, Stéphane Oudard	4
7	Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study 2021 ·Cancers ·Nicolas Delanoy, Debbie Robbrecht, Mario A. Eisenberger, Oliver Sartor, Ronald de Wit, Florence Mercier, Christine Geffriaud-Ricouard, Johann S. de Bono, Stéphane Oudard	5
8	Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study 2021 ·Lung Cancer ·Nicolas Epaillard, José Carlos Benítez, (unknown), Elizabeth Fabre, Mariona Riudavets, Roxana Reyes, David Planchard, Stéphane Oudard, Núria Viñolas, Noemı́ Reguart, Benjamin Besse, Laura Mezquita, Édouard Auclin	12
9	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial 2018 ·Journal of Clinical Oncology ·Bernard Escudier, Thomas Powles, Robert J. Motzer, Thomas Olencki, Osvaldo Arén Frontera, Stéphane Oudard, Frédéric Rolland, Piotr Tomczak, Daniel Castellano, Leonard J. Appleman, Harry A. Drabkin, Daniel A. Vaena, Steven Milwee, (unknown), Julie C. Lougheed, Sergio Bracarda, Toni K. Choueiri	121
10	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma 2017 ·Clinical Cancer Research ·Nicolás A. Giraldo, Étienne Becht, Yann Vano, Florent Petitprez, Laetitia Lacroix, Pierre Validire, Rafael Sanchez‐Salas, Alexandre Ingels, Stéphane Oudard, Audrey Moatti, Bénédicte Buttard, Sarah Bourass, Claire Germain, Xavier Cathelineau, Wolf H. Fridman, Catherine Sautès‐Fridman	263
11	Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma 2016 ·Cancer Research ·Clémence Granier, Charles Dariane, Pierre Combe, Virginie Verkarre, Saı̈k Urien, Cécile Badoual, Hélène Roussel, Marion Mandavit, Patrice Ravel, Mathilde Sibony, Lucie Biard, C. Radulescu, Emeline Vinatier, Nadine Benhamouda, Michaël Peyromaure, Stéphane Oudard, Arnaud Méjean, Marc‐Olivier Timsit, Alain Gey, Éric Tartour	163
12	Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation 2016 ·Cancer Research ·Sophie Bernichtein, Natascha Pigat, Nicolas Barry Delongchamps, Florence Boutillon, Virginie Verkarre, Philippe Camparo, Edouard Reyes‐Gomez, Arnaud Méjean, Stéphane Oudard, Eve M. Lepicard, Mélanie Viltard, Jean-Claude Souberbielle, Gérard Friedlander, Thierry Capiod, Vincent Goffin	42
13	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting 2015 ·Clinical Cancer Research ·Benoit Beuselinck, Sylvie Job, Étienne Becht, Alexandra Karadimou, Virginie Verkarre, Gabrielle Couchy, Nicolás A. Giraldo, Nathalie Rioux‐Leclercq, Vincent Molinié, Mathilde Sibony, Réza Elaidi, (unknown), Jean‐Jacques Patard, Arnaud Méjean, Wolf H. Fridman, Catherine Sautès‐Fridman, Aurélien de Reyniès, Stéphane Oudard, Jessica Zucman‐Rossi	230
14	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer breakdown → 2015 ·Clinical Cancer Research ·Nicolás A. Giraldo, Étienne Becht, Franck Pagès, Georgios Skliris, Virginie Verkarre, Yann Vano, Arnaud Méjean, Nicolas Saint-Aubert, Laetitia Lacroix, Ivo Natario, Audrey Lupo, Marco Alifano, Diane Damotte, Aurélie Cazes, Frédéric Triebel, Gordon J. Freeman, Marie‐Caroline Dieu‐Nosjean, Stéphane Oudard, Wolf H. Fridman, Catherine Sautès‐Fridman	356
15	Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin 2013 ·Clinical Cancer Research ·Romain Remark, Marco Alifano, Isabelle Cremer, Audrey Lupo, Marie‐Caroline Dieu‐Nosjean, Marc Riquet, Lucile Crozet, Hanane Ouakrim, Jérémy Goc, Aurélie Cazes, Jean–François Fléjou, Laure Gibault, Virginie Verkarre, Jean‐François Régnard, (unknown), Stéphane Oudard, Bernhard Mlecnik, Catherine Sautès‐Fridman, Wolf H. Fridman, Diane Damotte	284
16	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma breakdown → 2009 ·Journal of Clinical Oncology ·Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin	1711
17	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial breakdown → 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, (unknown), Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski	864
18	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial breakdown → 2008 ·The Lancet ·Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud	2339
19	Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma 2007 ·Journal of Clinical Oncology ·Toni K. Choueiri, A. Plantade, Paul Elson, Sylvie Négrier, Alain Ravaud, Stéphane Oudard, Ming Zhou, Brian I. Rini, Ronald M. Bukowski, Bernard Escudier	311
20	[Prostate cancer: update]. 2005 ·PubMed ·Stéphane Oudard, Jacques Médioni, Florian Scotté, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact